Patients with Crohn's disease are at increased risk of osteoporosis.
Disease activity and circulating proinflammatory cytokines are thought to play a role in this process.
Infliximab, a chimaeric antitumour necrosis factor- antibody is effective in the treatment of Crohn's disease.
Dr Ryan and colleagues undertook a study to investigate the impact of treatment with infliximab on bone turnover in Crohn's disease patients.
The investigators designed a prospective trial including 24 patients with active Crohn's disease who were treated with infliximab (5 mg/kg).
|Researchers found no significant change in the bone resorption marker|
|Alimentary Pharmacology and Therapeutics|
Bone markers were assayed pre- and post-treatment.
The researchers measured bone formation using serum bone-specific alkaline phosphatase and total osteocalcin and bone resorption using serum N-telopeptide cross-linked type 1 collagen.
The research group found that infliximab therapy caused a significant increase in both markers of bone formation in patients with active Crohn's disease.
However, the researchers found no significant change in the bone resorption marker serum N-telopeptide cross-linked type 1.
Dr Ryan concluded, "Infliximab therapy had a significant beneficial effect on bone metabolism in patients with active Crohn's disease."
"These findings further support the theory that active ongoing inflammation and high levels of circulating cytokines play a pivotal role in the pathogenesis of bone loss in patients with Crohn's disease."